Overview

Bioequivalence Study of Sumatriptan 100mg Tablets Under Fed Conditions

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To access the single-dose oral bioequivalence of sumatriptan succinate 100 mg tablet (containing 140 mg of sumatriptan succinate equivalent to 100 mg of sumatriptan) of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceutical Inc. USA) with IMITREX® 100 mg tablet (containing 140 mg of sumatriptan succinate equivalent to 100 mg of sumatriptan) of GlaxoSmithKline in healthy, adult, male, human subjects under fed condition.
Phase:
N/A
Details
Lead Sponsor:
Ranbaxy Laboratories Limited
Treatments:
Sumatriptan